Rezolute completes enrollment in Phase 3 ersodetug trial for tumor hyperinsulinism
RZLT•Rezolute completed enrollment of 16 participants in its Phase 3 upLIFT trial, with topline results expected in mid-December 2026. Previously reported results showed seven of the first eight participants met the primary endpoint and stopped intravenous glucose treatment.
1. Trial enrollment complete
Rezolute completed enrollment of 16 participants in its Phase 3 upLIFT trial of ersodetug for tumor hyperinsulinism. Topline results are expected in mid-December 2026.
2. Earlier results and safety
Seven of the first eight participants met the primary endpoint, and all seven stopped intravenous glucose treatment. No drug-related safety findings have been reported so far. The eighth participant died from cancer progression shortly after enrollment and was counted as a nonresponder.
